Erythropoietin-induced hypertension in rat is not mediated by alterations of plasma endothelin, vasopressin, or atrial natriuretic peptide levels

Journal of the American Society of Nephrology

Volumn 8, Issue 6, 1997, Pages 901-905

  Zhou, Xin Jin ^a   Pandian, Deepa ^a   Wang, Xiu Q ^a   Vaziri, Nosratola D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ENDOTHELIN; ERYTHROPOIETIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030869112     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW: Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens 3: 947-955, 1990
2. Abraham PA, Macres MG: Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 2: 927-936, 1991
3. Van de Borne P, Tielemans C, Vanherwegham JL, Degaute JP: Effect of recombinant human erythropoietin therapy on ambulatory blood pressure and heart rate in chronic hemodialysis patients. Nephrol Dial Transplant 1: 45-49, 1992
4. Maschio G: Erythropoietin and systemic hypertension. Nephrol Dial Transplant 10[Suppl 2]: 74-79, 1995
5. Vaziri ND, Zhou XJ, Smith J, Oveisi F, Baldwin K, Purdy RE: In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol 269: F838-F845, 1995
6. Vaziri ND, Zhou XJ, Naqvi F, Smith J, Oveisi F, Wang ZQ, Purdy RE: Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 271: E113-E122, 1996
7. Takahashi K, Totsune K, Imai Y, Sone M, Nozuki M, Murakami O, Sekino H, Mouri T: Plasma concentrations of immunoreactive endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci (Colch) 84: 47-50, 1993
8. Carlini R, Obialo CI, Rothstein M: Intravenous erythropoietin administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 6: 103-107, 1993
9. Lai KN, Lui SF, Leung JCK, Law E, Nicholls MG: Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron 57: 394-400, 1991
10. Brunet P, Lorec AM, Leonetti F, Roubicek C, Jaber K, Roux F, Berland Y: Plasma endothelin in hemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 9: 650-654, 1994
11. Hon GG, Vaziri ND, Kaupke CJ, Tehranzadeh A, Barton CH: Lack of a fast-acting effect of erythropoietin on arterial blood pressure and endothelin level. Artif Organs 19: 188-191, 1995
12. Skowsky WR, Rosenbloom AA, Fisher DA: Radioimmunoassay measurement of arginine vasopressin in serum: Development and application. J Clin Endocrinol Metab 38: 278-287, 1974
13. Yandle TG, Espiner EA, Nicholls MG, Dutt H: Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab 63: 72-79, 1986
14. Pandian MR, Lam RW, Castro L, Fisher DA: Radioimmunoassay for atrial natriuretic peptide in human plasma [Abstract]. Clin Chem 32: 1071, 1986
15. Yoshizumi M, Kurihara H, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Yazaki Y: Hemodynamic sheer stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun 161: 859-864, 1989
16. Yoshizumi M, Kurihara H, Morita T, Yamashita T, Oh-hashi Y, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Yazaki Y: Interleukin-1 increases the production of endothelin-1 by cultured endothelial cells. Biochem Biophys Res Commun 166: 324-329, 1990
17. Kanse SM, Takahashi K, Lam HC, Rees A, Warren JB, Port M, Molinatti P, Ghatei MN, Bloom SR: Cytokine stimulated endothelin release from endothelial cells. Life Sci 48: 1379-1384, 1991
18. Lerman AL, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325: 997-1001, 1991
19. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W, Binder BR: Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267: 16066-16068, 1992
20. Anggard E, Galton S, Rae G, Thomas R, McLoughlin L, de Nucci G, Vane JR: The fate of radioiodinated endothelin-1 and endothelin-3 in the rat. J Cardiovasc Pharmacol 13[Suppl 5]: 46-49, 1989
21. Pohl U, Busse R: Differential vascular sensitivity to luminally and adventitially applied endothelin-1. J Cardiovasc Pharmacol 13[Suppl 5]: 188-190, 1989
22. Kokot F, Wiecek A, Schmidt-Gayk H, Marcinkowski W, Gilge U, Heidland A, Rudka R, Trembecki J: Function of endocrine organs in hemodialyzed patients of long-term erythropoietin therapy. Artif Organs 19: 428-435, 1995
23. Kokot F, Wiecek A, Grzeszczak W, Klin M: Influence of erythropoietin treatment on plasma renin activity, Aldosterone, vasopressin and atrial natriuretic peptide in hemodialyzed patients. Miner Electrolyte Metab 16: 25-29, 1990
24. Ono K, Hisasue Y: The rate of increase in hematocrit, humoral vasoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion. Clin Nephrol 37: 23-27, 1992
25. Takayama K, Nagai T, Kinugasa E, Akizawa T, Koshikawa S: Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patients. Trans Am Soc Artif Intern Organs 37: 187-188, 1991